Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Response to mRNA COVID-19 vaccination in three XLA patients

J.D. Squire a,⇑, A.Y. Joshi b

a Division of Pulmonary, Allergy and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA
b Division of Pediatric Allergy & Immunology, Mayo Clinic Children’s Center, Rochester, MN, USA

A R T I C L E   I N F O

Article history:
Received 13 August 2021
Received in revised form 29 June 2022
Accepted 28 July 2022
Available online 3 August 2022

Keywords:
COVID-19
Vaccine
Inborn error of immunity
X-linked agammaglobulinemia
Immunodeficiency

A B S T R A C T

X-linked agammaglobulinemia (XLA) is an inborn error of immunity characterized by insufficient production of immunoglobulins and lack of measurable antibody response to vaccines. The rise of novel infections limits the protective effect of immunoglobulin replacement in immunodeficient patients though. While XLA patients are not expected to mount an antibody response to COVID-19 vaccination, it has been demonstrated that XLA patients can mount a T-cell response to COVID-19 vaccines, similar to the influenza vaccine. We present three patients with XLA who received an mRNA COVID-19 vaccine. One patient demonstrated positive antibody response. Many XLA patients do not receive routine vaccinations due to ongoing immunoglobulin replacement therapy and lack of native antibody production, but in addition to T-cell response to vaccination, select XLA patients may mount a positive antibody response. Therefore, COVID-19 vaccination should be encouraged for all XLA patients.

© 2022 Elsevier Ltd. All rights reserved.

1. Introduction

X-linked agammaglobulinemia (XLA) was one of the first identified inborn errors of immunity (IEI) characterized by defective B-cell development resulting in B-cell lymphopenia (usually < 2 %) due to mutations in the Bruton tyrosine kinase (BTK) gene on the X-chromosome [1]. This results in significantly reduced levels of all immunoglobulins and ineffective specific antibody production. Milder mutations in BTK have been associated with some residual function resulting in older age of diagnosis, higher than expected immunoglobulin levels, and increased B cells counts compared to other mutations considered more severe [2,3]. The primary treatment for XLA is immunoglobulin replacement, either intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG), which offers protection against many vaccine-preventable diseases with high titers, except for certain viral antigens such as each yearly circulating influenza strain [4]. Antibody deficiencies are most commonly associated with risk of bacterial sinopulmonary infections, but patients with XLA have also demonstrated increased risk of viral infections, such as chronic enterovirus meningoencephalitis [5]. While patients with XLA typically do not mount significant antibody response to vaccination, it has been shown that they can produce normal virus-specific T-cell responses to the inactivated influenza vaccine [6]. Due to the risk of vaccine associated illness, it is generally recommended to avoid live vaccination in patients with XLA, and routine inactivated vaccines are typically not given due to the lack of response and ongoing treatment with immunoglobulin replacement.[7] Yearly inactivated influenza vaccine is recommended in virtually all patients with XLA due to the low antibody levels for current influenza strains in the supplemental immunoglobulin preparations.[4,7] Data on response to COVID-19 vaccination in patients with immunodeficiency is growing, several case series and studies have now been published demonstrating encouraging results for humoral and cellular response to the vaccines in this group.[8–10] We present 3 patients (one previously reported[8]) with XLA, to further demonstrate the effectiveness and heterogeneity of antibody response to COVID-19 vaccination in IEI. All patients had no prior history of COVID-19 infection.

Patient case information was obtained from retrospective chart review as part of an institutional review board approved study.

2. Case series

Patient #1 is 47-year-old male with XLA and bronchiectasis receiving IVIG 40 g monthly. Current immunomodulation includes hydroxychloroquine for chronic lower extremity rash likely
consistent with erythema nodosum. The patient has a known pathogenic hemizygous variant in BTK (c.763C > T, p.Arg255) resulting in a premature stop codon. Flow cytometry demonstrated absent CD19+ and CD20+ B-cells. Btk protein expression was reduced in monocytes (patient’s MFI = 1.23, control MFI = 4.31), consistent with XLA. His most recent immunoglobulin levels (on IVIG) were IgG 1090 mg/dL, IgA < 1 mg/dL, and IgM < 5 mg/dL. Two weeks following his second dose of Pfizer mRNA COVID-19 vaccination, in May 2021, SARS-CoV-2 spike antibodies were negative (<0.80 U/mL) as well as negative SARS-CoV-2 nucleocapsid antibodies. See Table 1.

Patient #2 is a 44-year-old male with XLA and bronchiectasis on IVIG 30 g every 3 weeks, with no additional immunomodulation. This patient was previously reported in a case series on response to COVID-19 vaccination in patients with immunodeficiency.[8] He has a variant in the BTK gene (c.1657delA, p.Ser553Alafs*3) creating a frame shift starting at codon Ser553 and resulting in a premature stop codon. He demonstrated absent CD19+ and CD20+ B-cells by flow cytometry and decreased Btk protein expression in monocytes (patient’s MFI = 2.36, control MFI = 7.88). Most recent immunoglobulin levels (on IVIG) were IgG 1060 mg/dL, IgA < 1 mg/dL, and IgM < 5 mg/dL. SARS-CoV-2 spike (<0.40 U/mL) and nucleocapsid antibodies were negative in March 2021, >4 weeks after the second dose of the Pfizer mRNA COVID-19 vaccine. See Table 1.

Patient #3 is 64-year-old male with XLA on IVIG 45 g monthly, on no additional immunomodulation. This patient was previously reported in a case series on response to COVID-19 vaccination in patients with immunodeficiency.[8] He has a variant in the BTK gene (c.76A > G, p.Lys26Glu), encoding the pleckstrin homology (PH) domain. Btk protein expression was reported as present intracellularly in B-cells and monocytes, and intracellular Btk protein expression appeared to be normal in monocytes. This patient has a strong family history of XLA, with diagnosis in 2 maternal cousins as well as his great-grandson. The patient’s most recent immunoglobulin levels (on IVIG) were IgG 896 mg/dL, IgA < 1 mg/dL, and IgM < 5 mg/dL. In April 2021, 2 weeks after 2 doses of Moderna mRNA COVID-19 vaccine, the patient had evidence of antibody response to the vaccine with positive SARS-CoV-2 spike antibodies (118 U/mL) and negative SARS-CoV-2 nucleocapsid antibodies (consistent with vaccination and not prior infection). See Table 1.

3. Discussion

With the onset of the COVID-19 pandemic, many patients with immunodeficiency have had significant concerns regarding risk of infection, complications, mortality, as well as effectiveness of prophylaxis and treatment strategies for COVID-19. Initially reported cases of COVID-19 infection in patients with congenital agammaglobulinemia suggested a mild course without significant complication but a more recent review of published cases of COVID-19 infection in XLA patients indicates that a cause for concern is not unfounded.[11,12] Ponsford et al identified 28 XLA patients with COVID-19 infection reported in the literature. Overall, 79 % (22/28) were admitted to the hospital with median length of stay of 22 days, 3 of which were admitted the intensive care unit. There was 1 reported death which equated to a 4 % overall mortality rate. [12].

Vaccination against COVID-19 infection has demonstrated dramatic effect on improving adverse outcomes, including hospitalizations and deaths, in the US population overall.[13] While there is less specific data on outcomes in patients with IEL, there has been growing data on the response to COVID-19 vaccination in immunodeficient patients. As expected, majority with XLA have not produced measurable antibody responses to COVID-19 vaccination, yet when assessed, almost all had positive T-cell response. Outcomes of vaccination in XLA patients identified from literature review are summarized in Table 2.[8,9,14–20] More recently, van Leeuwen at al published the response to mRNA COVID-19 vaccination a cohort of adult patients with IEL. Nineteen patients with XLA were included, 3 of which had positive antibody response.[10] Our case series supports their findings, that certain subsets of XLA patients may be able to produce a humoral, in addition to a cellular

### Table 1

| Patient # | Age (yrs) | Mutation in BTK | Intracellular Btk Protein Expression | Absolute B-cell Count (cells/mcL) | SARS-CoV-2 Spike Ab (U/mL) | SARS-CoV-2 Nucleocapsid (Total Ab) |
|-----------|-----------|-----------------|-------------------------------------|----------------------------------|----------------------------|-----------------------------------|
| 1         | 47        | c.763C > T, p.Arg255 | ↓                                   | 0                                | Negative (<0.80)             | Negative                           |
| 2         | 44        | c.1657delA, p.Ser553Alafs*3 | ↓                                   | 0                                | Negative (<0.40)             | Negative                           |
| 3         | 64        | c.76A > G, p.Lys26Glu | Normal                             | 1                                | Positive (118)               | Negative                           |

Ab = antibodies.

### Table 2

| Paper | Number of XLA patients Assessed | Type of Vaccine Received | Number with Positive Antibody Response (%) | Number with Positive Cellular Response (%) |
|-------|---------------------------------|--------------------------|--------------------------------------------|------------------------------------------|
| Oshiro et al [17] | 1 | CoronaVac | 0 (0 %) | 1 (100 %) |
| Ponsford et al [18] | 3 | AstraZeneca or mRNA | 0 (0 %) | NA |
| Shields et al [19] | 9 | AstraZeneca or mRNA | 0 (0 %) | NR |
| Squire & Joshi [8] | 1 | Pfizer mRNA | 0 (0 %) | NA |
| Hagin et al [9] | 4 | Pfizer mRNA | 0 (0 %) | 4 (100 %) |
| Salinas et al [14] | 6 | Pfizer mRNA | 0 (0 %) | 5 (83 %) |
| Bergman et al [15] | 4 | Pfizer mRNA | 0 (0 %) | NA |
| Delmonte & Bergerson et al [16] | 1 | Moderna mRNA | 0 (0 %) | NA |
| Pham et al [20] | 1 | Moderna mRNA | 0 (0 %) | 1 (100 %) |
| van Leeuwen et al [10] | 19 | Moderna mRNA | 3 (15 %) | 19 (100 %) |

XLA = X-linked agammaglobulinemia; NA = not assessed; NR = not reported.
immune response, due to residual B-cell function. While majority of patients with XLA have classical features, there can be a heterogeneity in presentation and severity based on the BTK mutation. [2,3] A known mutation in the BTK gene may not exclude the ability for patients with XLA to mount a positive antibody response to vaccination. Btk protein expression may help differentiate those with the ability to respond, as patient #3 who had normal intracellular Btk expression in monocytes and who did mount a humoral immune response, as compared to decreased Btk expression found in patients #1 and #2.

While studies have demonstrated rising anti-SARS-CoV-2 antibodies in commercially available immunoglobulin products[19], it is unlikely that the results in patient #3 are due to spike antibodies in differing lots or IVIG products. All three patients received vaccination at the beginning of 2021 when COVID-19 vaccines first became available to high-risk patients [between March-May 2021], which would not have been enough elapsed time for vaccinated plasma donors to contribute to the currently available IVIG at the time. As the nucleocapsid antibodies were negative, this indicates that the positive spike antibodies were not due to natural infection antibodies either. It still remains unclear what antibody level is needed for protection and whether passive immunity itself would be enough to prevent infection, especially in the context of variant strains. Our report provides additional support for the safety and efficacy of mRNA COVID-19 vaccination in patients with XLA. Therefore, COVID-19 vaccination should be encouraged in patients with XLA.

Funding source
None.

Data availability
No data was used for the research described in the article.

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References
[1] El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, et al. X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J 2019;12(3):100018.
[2] Cardenas-Morales M, Hernandez-Trujillo VP. Agammaglobulinemia: from X-linked to Autosomal Forms of Disease. Clin Rev Allergy Immunol 2022;63(1):22–35.
[3] Gaspar HB, Conley ME. Early B cell defects. Clin Exp Immunol 2000;119(3):383–9.
[4] Milito C, Soccodato V, Collatti G, Lanciarotta A, Bertozzi I, Rattazzi M, et al. Vaccination in PADs. Vaccines (Basel) 2021;9(6):626.
[5] Jones TPW, Buckland M, Breuer J, Lowe DM. Viral infection in primary antibody deficiency syndromes. Rev Med Virol 2019;29(4):e2049.
[6] Liu Y, Wu Y, Lam KT, Lee PP, Tu W, Lau YL. Dengritic and T cell response to influenza is normal in the patients with X-linked agammaglobulinemia. J Clin Immunol 2012;32(3):421–9.
[7] Sohh A, Bonilla FA. Vaccination in Primary Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2016;4(6):1066–75.
[8] Squire J, Joshi A. Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency. Ann Allergy Asthma Immunol 2021;127(3):383–4.
[9] Hagn D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol 2021;148(3):739–49.
[10] van Leeuwen LPM, GeurtsvanKessel CH, Ellenbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. J Allergy Clin Immunol 2022;149(6):1949–57.
[11] Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lessons from patients with agammaglobulinemia. J Allergy Clin Immunol 2020;146(1):211–213.e4.
[12] Ponsford MJ, Shiltitoe BMJ, Humphreys IR, Gennery AR, Jolles S. COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency. Curr Opin Allergy Clin Immunol 2021;21(6):525–34.
[13] Moghadas SM, Yiliches TW, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin Infect Dis 2021;73(12):2257–64.
[14] Salinas AF, Mortari EP, Terreni S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best. J Clin Immunol 2021;41(8):1709–22.
[15] Bergman P, Blennow D, Hansson L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 2021;74:103705.
[16] Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with varying inborn errors of immunity. J Allergy Clin Immunol 2021;148(5):1192–7.
[17] Oshiro TM, da Silva LT, Ortega MM, Perazzia SF, Duarte AdjS, Carneiro-Sampaio M. Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine. Clinics (Sao Paulo) 2022;77:100007.
[18] Ponsford MJ, Evans K, Carne EM, Jolles S, Bramhall K, Grant L, et al. COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort. J Clin Immunol 2022;42(4):728–31.
[19] Shields AM, Faustini SE, Hill HJ, et al. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study. J Clin Immunol 2021;1–12.
[20] Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. J Allergy Clin Immunol 2022;149(3):907–911.e3.
[21] Romero C, Diez JM, Cajardo R. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products. Lancet Infect Dis 2021;21(6):765–6.